TELA Bio (NASDAQ: TELA) Q2 loss widens, revenue dips and 2026 guidance withdrawn
Rhea-AI Filing Summary
TELA Bio reported second quarter 2026 revenue of $19.3 million, down 4% from $20.2 million a year earlier, as OviTex PRS volumes declined and price/mix pressures in hernia procedures persisted. Gross profit was $13.9 million, with gross margin improving to 72% from 70%, helped by a tariff refund and lower excess and obsolete inventory charges.
Operating expenses held flat at $23.2 million, but net loss widened to $11.3 million from $9.9 million. As of June 30, 2026, cash and cash equivalents were $30.4 million, long-term debt was $56.1 million, and stockholders’ equity shifted to a $15.9 million deficit from positive $6.3 million at year-end 2025. Management withdrew full-year 2026 revenue guidance while the new CEO reviews strategy, citing the need to improve PRS performance, accelerate hernia market share gains, and take decisive actions to extend the cash runway and align costs with the top line. Hernia unit volumes grew 12% year over year, and international revenue continued to increase.
Positive
- Hernia unit volumes grew 12% year over year, indicating continued procedural market share gains despite overall revenue declining.
- Gross margin improved to 72% from 70% in the prior-year quarter, supported by a tariff refund and lower excess and obsolete inventory charges.
Negative
- Net loss increased to $11.3 million from $9.9 million in the prior-year quarter, reflecting higher interest expense and ongoing operating losses.
- Stockholders’ equity turned to a $15.9 million deficit at June 30, 2026, from positive $6.3 million at December 31, 2025, highlighting balance sheet pressure.
- Full-year 2026 revenue guidance was withdrawn as the new CEO reassesses strategy amid softness in PRS volumes and competitive pricing and bundling dynamics.
Filing Explained
TELA reported 44,833,942 shares outstanding at June 30 versus 44,538,264 at December 31, indicating potential dilution; its results release was furnished, not filed.
This Form 8-K furnishes TELA Bio’s second-quarter 2026 results release under Item 2.02; the release is furnished rather than treated as filed under Section 18 or incorporated by reference unless expressly referenced. The balance sheet reports 44,833,942 common shares issued and outstanding at June 30, 2026, up from 44,538,264 at December 31, 2025, a change that can reduce existing holders’ percentage ownership absent offsetting changes.
The disclosed figures therefore support potential dilution from the higher reported share count, but they do not establish the transaction mechanics behind the change.
8-K Event Classification
Key Figures
Key Terms
bundling financial
cash runway financial
stockholders’ (deficit) equity financial
forward-looking statements regulatory
Earnings Snapshot
Full-year 2026 revenue guidance withdrawn; company will provide an update in the future.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
How did TELA (TELA) perform financially in Q2 2026?
What is TELA (TELA) saying about its 2026 revenue guidance?
What is TELA (TELA)’s cash position and debt as of June 30, 2026?
Did TELA (TELA) show any operational growth in Q2 2026?
How did margins and operating expenses trend for TELA (TELA) in Q2 2026?
What is the new CEO of TELA (TELA) prioritizing going forward?
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including
area code: (
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) |
Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
| Item 2.02 | Results of Operations and Financial Condition. |
On August 10, 2026, TELA Bio, Inc. (the “Company”) issued a press release announcing its financial results for the second quarter ended June 30, 2026. A copy of this press release is furnished as Exhibit 99.1 hereto.
The information furnished pursuant to this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits
The following exhibits are being furnished herewith:
| Exhibit No. | Document | |
| 99.1 | Press Release of TELA Bio, Inc., dated August 10, 2026. | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| TELA BIO, INC. | ||
| By: | /s/ Heather Getz | |
| Name: | Heather Getz | |
| Title: | Chief Executive Officer and Director | |
Date: August 10, 2026
Exhibit 99.1
TELA Bio Reports Second Quarter 2026 Financial Results
MALVERN, PA, August 10, 2026 -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the second quarter ended June 30, 2026.
Recent Highlights
| ● | Announced appointment of Heather Getz as Chief Executive Officer and Director, effective August 4, 2026; |
| ● | Delivered international revenue growth of 26% over the prior year period, with continued momentum in several European markets; |
| ● | Achieved additional market share gain with OviTex unit volume growth of 12% over the prior year period; |
| ● | Grew LiquiFix revenue by 39% over the prior-year period; and |
| ● | Delivered $19.3 million revenue in the second quarter of 2026, representing a decline of 4% from the prior year period, primarily the result of a decline in OviTex PRS unit volumes. |
“I am honored to join TELA Bio at such an exciting time in the Company's evolution. One reason I joined TELA is the superiority of our differentiated product portfolio. OviTex long-term data has continuously shown recurrence rates in the low single-digits, whereas other hernia repair materials have recurrence rates consistently 10 times higher than that.
“Unfortunately, the financial performance of the business does not reflect the superiority of the portfolio. Our second quarter revenue was negatively impacted by a decline in OviTex PRS volumes and continued price and mix headwinds in hernia procedures. In response, we have returned to a sales structure designed to reinforce cross-selling among our field teams, and with a clear focus on returning to growth in the second half the year,” said Heather Getz, newly appointed Chief Executive Officer of TELA Bio.
“We also continue to battle against the competitive dynamics of bundling from our largest competitors and to combat this, we have upgraded talent within our Market Access and Contracting team. We are encouraged by several indicators of progress across the business. Hernia unit volumes grew 12% year over year, demonstrating continued procedural market share gains, while ASP and procedure mix begin to stabilize. International revenue also continued to grow, and our field organization is progressing toward the productivity levels we expected as newer territory managers gain experience."
Ms. Getz continued, “Given the confluence of these dynamics, we are withdrawing our full year 2026 revenue guidance as I fully assess the business and strategic direction. What is clear to me is that as we move through the second half of the year, we must improve PRS performance, accelerate our market share gains in hernia, and translate the increasing productivity of our commercial organization into sustainable top-line growth. At the same time, we will take decisive action to extend our cash runway and better align our cost structure with our top line. We are focused on disciplined execution and creating long-term value for all our stakeholders.”
Second Quarter 2026 Financial Results
Revenue was $19.3 million in the second quarter of 2026, a decrease of 4% compared to $20.2 million in the second quarter of 2025. The decrease was primarily driven by a decline in OviTex PRS volumes and price mix headwinds, partially offset by growing international sales.
Gross profit was $13.9 million, or 72% of revenue, in the second quarter of 2026, compared to $14.1
million, or 70% of revenue, in the same period in 2025. The increase in gross margin was primarily due to a tariff refund and a lower charge for excess and obsolete inventory as a percentage of revenue.
Operating expenses were $23.2 million in both the second quarter of 2026 and 2025. There was a de minimis increase due to higher meeting and training costs and increased professional fees partially offset by lower compensation and benefits from lower headcount, lower commission expense, and lower study costs.
Loss from operations was $9.3 million in the second quarter of 2026, compared to $9.1 million in the same period in 2025.
Net loss was $11.3 million in the second quarter of 2026, compared to a net loss of $9.9 million in the same period in 2025.
Cash and cash equivalents on June 30, 2026 were $30.4 million.
2026 Financial Guidance
The Company has withdrawn full-year guidance and will provide an update in the future.
Conference Call
TELA Bio will host a conference call at 4:30 p.m. Eastern Time on Monday, August 10, 2026 to discuss its second quarter financial results. Investors interested in listening to the conference call should register online. Participants are required to register a day in advance or at minimum 15 minutes before the start of the call. A replay of the webcast can be accessed via the Events & Presentations page of the investor section of TELA Bio's website.
About TELA Bio, Inc.
TELA Bio, Inc. (NASDAQ: TELA) is a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy. The Company is committed to providing surgeons with advanced, economically effective soft-tissue reconstruction solutions that leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. For more information, visit www.telabio.com.
Caution Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations are forward-looking statements and reflect the current beliefs of TELA Bio's management. Such forward-looking statements include statements relating to our expected revenue and revenue growth for the full year 2026 and reduction in operating expenses throughout the full year 2026 compared to prior periods and our expectations regarding new product launch and expectations on market penetration and profitability. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated by such forward-looking statements including, among others: the impact to our business from macroeconomic conditions, including recessionary concerns, banking instability, increasing market interest rates, monetary policy changes, changes in trade policies, including tariffs and trade protection measures, and inflationary pressures, potentially impacting our ability to market our products, including the launch of new products; demand for our products related to changes in volumes or frequency of surgical procedures, including due to outbreak of illness or disease, cybersecurity events impacting hospital operations, potential hospital closures, labor and hospital staffing shortages, supply chain disruptions to critical surgical and hospital supplies, pricing pressures or any other applicable adverse healthcare economic factors; our ability to achieve or sustain profitability; our ability to gain market acceptance for our products and to accurately forecast and meet customer demand; our ability to compete successfully; that data from earlier studies related to our products and interim data from ongoing studies may not be replicated in later studies or indicative of future data; that data obtained from clinical studies using our product may not be indicative of outcomes in other surgical settings; our ability to enhance our product offerings, including successful launch of new products; our ability to maintain expanded market access; product development and manufacturing problems; capacity constraints or delays in production of our products; maintenance of coverage and adequate reimbursement for procedures using our products; and product defects or failures. These risks and uncertainties are described more fully in the “Risk Factors” section and elsewhere in our filings with the Securities and Exchange Commission and available at www.sec.gov, including in our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Any forward-looking statements that we make in this announcement speak only as of the date of this press release, and TELA Bio assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise after the date of this press release, except as required under applicable law.
Investor Contact
Louisa Smith
ir@telabio.com
TELA Bio, Inc.
Consolidated Balance Sheets
(In thousands, except share and per share amounts)
(Unaudited)
| June 30, | December 31, | |||||||
| 2026 | 2025 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 30,424 | $ | 50,845 | ||||
| Accounts receivable, net of allowances of $522 and $287 | 9,637 | 10,347 | ||||||
| Inventory | 11,059 | 11,016 | ||||||
| Prepaid expenses and other current assets | 3,371 | 3,373 | ||||||
| Total current assets | 54,491 | 75,581 | ||||||
| Property and equipment, net | 2,048 | 2,226 | ||||||
| Intangible assets, net | 1,169 | 1,359 | ||||||
| Right-of-use assets | 1,379 | 1,502 | ||||||
| Other long-term assets | 451 | 500 | ||||||
| Restricted cash | 200 | 250 | ||||||
| Total assets | $ | 59,738 | $ | 81,418 | ||||
| Liabilities and stockholders’ (deficit) equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 2,883 | $ | 2,309 | ||||
| Accrued expenses and other current liabilities | 15,335 | 15,666 | ||||||
| Total current liabilities | 18,218 | 17,975 | ||||||
| Long-term debt | 56,081 | 55,653 | ||||||
| Other long-term liabilities | 1,305 | 1,477 | ||||||
| Total liabilities | 75,604 | 75,105 | ||||||
| Stockholders’ (deficit) equity: | ||||||||
| Preferred stock; $0.001 par value: 10,000,000 shares authorized; no shares issued and outstanding | — | — | ||||||
| Common stock; $0.001 par value: 200,000,000 shares authorized; 44,833,942 and 44,538,264 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively | 45 | 44 | ||||||
| Additional paid-in capital | 405,101 | 403,739 | ||||||
| Accumulated other comprehensive income | 84 | 91 | ||||||
| Accumulated deficit | (421,096 | ) | (397,561 | ) | ||||
| Total stockholders’ (deficit) equity | (15,866 | ) | 6,313 | |||||
| Total liabilities and stockholders’ (deficit) equity | $ | 59,738 | $ | 81,418 | ||||
TELA Bio, Inc.
Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except share and per share amounts)
(Unaudited)
| Three months ended June 30, | Six months ended June 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Revenue | $ | 19,291 | $ | 20,197 | $ | 38,350 | $ | 38,717 | ||||||||
| Cost of revenue (excluding amortization of intangible assets) | 5,253 | 5,997 | 11,697 | 11,910 | ||||||||||||
| Amortization of intangible assets | 95 | 95 | 190 | 190 | ||||||||||||
| Gross profit | 13,943 | 14,105 | 26,463 | 26,617 | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Sales and marketing | 16,442 | 16,857 | 32,979 | 33,465 | ||||||||||||
| General and administrative | 4,061 | 4,126 | 8,227 | 7,962 | ||||||||||||
| Research and development | 2,723 | 2,203 | 5,066 | 4,743 | ||||||||||||
| Total operating expenses | 23,226 | 23,186 | 46,272 | 46,170 | ||||||||||||
| Loss from operations | (9,283 | ) | (9,081 | ) | (19,809 | ) | (19,553 | ) | ||||||||
| Other (expense) income: | ||||||||||||||||
| Interest expense | (2,076 | ) | (1,188 | ) | (4,129 | ) | (2,407 | ) | ||||||||
| Other income | 157 | 379 | 523 | 858 | ||||||||||||
| Total other expense, net | (1,919 | ) | (809 | ) | (3,606 | ) | (1,549 | ) | ||||||||
| Loss before income tax expense | (11,202 | ) | (9,890 | ) | (23,415 | ) | (21,102 | ) | ||||||||
| Income tax expense | (60 | ) | (33 | ) | (120 | ) | (85 | ) | ||||||||
| Net loss | $ | (11,262 | ) | $ | (9,923 | ) | $ | (23,535 | ) | $ | (21,187 | ) | ||||
| Net loss per common share, basic and diluted | $ | (0.20 | ) | $ | (0.22 | ) | $ | (0.41 | ) | $ | (0.47 | ) | ||||
| Weighted average common shares outstanding, basic and diluted | 57,414,360 | 45,365,325 | 57,335,875 | 45,316,444 | ||||||||||||
| Comprehensive loss: | ||||||||||||||||
| Net loss | $ | (11,262 | ) | $ | (9,923 | ) | $ | (23,535 | ) | $ | (21,187 | ) | ||||
| Foreign currency translation adjustment | (1 | ) | 2 | (7 | ) | 3 | ||||||||||
| Comprehensive loss | $ | (11,263 | ) | $ | (9,921 | ) | $ | (23,542 | ) | $ | (21,184 | ) | ||||